Review charts CADD pipeline gaps; no fresh data

Today's Overview

Review maps CADD workflow but adds no new data Manuscript is a narrative review, not a research article, and contains no quantitative performance data.

Featured

01Review maps CADD workflow but adds no new data

The paper recaps how computer-aided drug design (CADD) is meant to compress the multi-year journey from hit to lead by replacing wet-lab iterations with ligand-based (QSAR, pharmacophore) and receptor-based (docking, de-novo) calculations. No new molecules, algorithms, or experimental validations are reported; the text simply walks through the standard virtual-screening cascade. Because no comparative metrics, benchmarks, or success rates are supplied, the review cannot tell practitioners which CADD steps actually accelerate discovery or improve potencies in vitro or in vivo.

Manuscript is a narrative review, not a research article, and contains no quantitative performance data.All described methods (QSAR, pharmacophore, docking, de-novo) are long-established CADD tools.No in silico, in vitro, or in vivo validation of any new compound or workflow is presented.

Source: A Novel Perspective In Drug Design And Drug Discovery (4d) With Computer-Aided Drug Design (Cadd): A Review

Also Worth Noting

Stability-validated meta-ensemble QSAR screens 16,196 compounds, yielding Mol-2 BACE1 inhibitor with 98-99% catalytic dyad occupancy and ROC-AUC 0.920Docking & Binding

Meta-ensemble QSAR, ESM-1b-weighted docking and 200-ns MD of 16,196 compounds deliver Mol-2 BACE1 inhibitor (ligand RMSD 1.2–1.6 Å, ROC-AUC 0.920) with sustained ASP32/228 interactions and predicted BBB permeability. link

Today's Observation

The review paper offers a consolidated map of the computer-aided drug design (CADD) pipeline, but practitioners should note it is purely narrative: no new algorithms, benchmarks, or compounds are introduced. Every technique catalogued—QSAR, pharmacophore matching, docking, and de-novo generation—has been standard for years, so the manuscript functions as a refresher rather than an innovation driver. For teams auditing existing workflows or onboarding junior modelers, the paper can serve as a checklist; however, those seeking quantitative performance gains or prospective validation will find no data to mine.

Key takeaway: treat the piece as a high-level orientation, not an evidence base. Without in silico, in vitro, or in vivo results, it cannot resolve ongoing practitioner questions such as which docking score cutoff reliably enriches true binders or how modern ML models compare with legacy QSAR. Until follow-up studies supply those metrics, the mapped workflow remains qualitative scaffolding rather than an actionable, benchmarked protocol.

The above is personal commentary for reference only. Refer to the original papers for authoritative content.